Holder | Position | Change | Date | |
---|---|---|---|---|
No active short positions |
Holder | Position | Change (%) | Date | |
---|---|---|---|---|
No historical short positions |
hVIVO is a contract research organization that conducts human challenge clinical trials for respiratory and infectious disease vaccines and therapeutics:
hVIVO offers services such as challenge trials, assay development, field trial bio-logistics, cell based assays, molecular services, compound efficacy and VRM, and biomarker analysis.
Formerly known as Retroscreen, hVIVO was renamed in 2015 when it went public on the London Stock Exchange.
hVIVO has a portfolio of 11 human challenge models, with more models in development. Their portfolio includes models for influenza, respiratory syncytial virus, human rhinovirus, asthma, COPD, cough, malaria, COVID-19, and hMPV.
hVIVO share price launched at 33p in 2012.